Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NX-5948 |
Synonyms | |
Therapy Description |
NX-5948 is a chimeric targeting molecule (CTM) comprised of a BTK binding element linked to Cereblon (CRBN), which potentially induces degradation of BTK and inhibition of tumor growth (Blood 2021 138 (Supp 1):2251). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NX-5948 | NX5948|NX 5948 | BTK inhibitor 37 | NX-5948 is a chimeric targeting molecule (CTM) comprised of a BTK binding element linked to Cereblon (CRBN), which potentially induces degradation of BTK and inhibition of tumor growth (Blood 2021 138 (Supp 1):2251). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05131022 | Phase I | NX-5948 | Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | NLD | GBR | 0 |